NPM1 and acute myeloid leukemia: KOMET-008 (NCT06001788) is another ongoing dose escalation and expansion study to check the tolerability, safety, and preliminary efficacy of ziftomenib with FLAG–idarubicin or low-dose cytarabine or gilteritinib for the treatment of either NPM1-m or KMT2Ar or NPM1-m with FLT3MT R/R AML.